Quick Answer
Cyclerion Therapeutics, Inc. reported R&D Expense of $959.0 thousand for fiscal year 2025.
Cyclerion Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $959.0K | +235.3% |
| 2024 | $286.0K | -81.1% |
| 2023 | $1.51M | -74.7% |
| 2022 | $5.98M | -84.1% |
| 2021 | $37.64M | -33.3% |
| 2020 | $56.41M | -40.7% |
| 2019 | $95.14M | +8.5% |
| 2018 | $87.72M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $348.0K | +329.6% | +521.4% |
| June 30, 2025 | $56.0K | -46.7% | +55.6% |
| March 31, 2025 | $36.0K | -18.2% | -55.6% |
| September 30, 2024 | $81.0K | -86.0% | -22.9% |
| June 30, 2024 | $105.0K | -69.0% | +138.6% |
| March 31, 2024 | $44.0K | -92.3% | -92.4% |
| September 30, 2023 | $580.0K | -59.0% | +71.1% |
| June 30, 2023 | $339.0K | -96.7% | -40.7% |
- Cyclerion Therapeutics, Inc. showed an increase of +235.3% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Cyclerion Therapeutics, Inc.’s r&d expense has declined by 98.9% (from $87.72 million to $959.0 thousand).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: